ReviewJournal of translational medicine2025
Multi-omics based and AI-driven drug repositioning for epigenetic therapy in female malignancies.
Review in Journal of translational medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- c-Medical sciences (Basel, Switzerland) · 2026Review
- From Laboratory to Patient Access: A Scoping Review of the Multi-Dimensional Challenges in Drug Repurposing.Pharmacy (Basel, Switzerland) · 2026Review
- Identification of LncRNAs scaffolding a chromatin-associated gene regulatory complex in breast cancer cells comprising ERα, DOT1L and menin.Cell communication and signaling : CCS · 2026Article
- PTM encoding: decoding the mechanisms of exercise-induced metabolic memory through spatiotemporal modification networks.Frontiers in sports and active living · 2026Review
- Tumor suppressor network dysregulation in neuroblastoma: molecular mechanisms and precision therapeutic opportunities.Frontiers in cell and developmental biology · 2026Review
- Breast cancer pathogenesis, diagnosis and treatment: a comprehensive review.Frontiers in oncology · 2026Review
- Multimodal artificial intelligence in urologic precision oncology: from algorithm to translational medicine (a systemized narrative review).Frontiers in oncology · 2026Review
- Bridging science and hope: the evolving story of gene therapy for neuromuscular diseases.Frontiers in cell and developmental biology · 2026Review
- From Methylomes to CRISPR Epigenetic Editing: New Paths in Antibiotic Resistance.Pathogens (Basel, Switzerland) · 2025Review
- Epigenetic Regulation of Autophagy in Breast Cancer: Implications for Biomarker Discovery and Personalized Therapy.Cancer reports (Hoboken, N.J.) · 2025Review
- Emerging hallmarks and the rise of complexities and heterogeneity of tumor.Biochemistry and biophysics reports · 2025Review
- Integrating New Approach Methodologies (NAMs) into Preclinical Regulatory Evaluation of Oncology Drugs.Biomimetics (Basel, Switzerland) · 2025Review
- AI-driven multi-omics integration in precision oncology: bridging the data deluge to clinical decisions.Clinical and experimental medicine · 2025Review
- MMP11 predicts colorectal cancer outcomes and its inhibitor RXP03 exerts anti-tumor effects via apoptosis activation.BMC gastroenterology · 2025Article
- Computational strategies in tumor phylogenetics: evaluating multimodal integration and methodological trade-offs across study designs.Bioinformatics advances · 2025Review
- Mapping the Landscape of Anti-Breast Cancer Drug Discovery in Saudi Arabia: A Bibliometric Analysis (2019-2023).Scientifica · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
Histone post-translational modifications (PTMs) have long been recognized as critical regulators of chromatin dynamics and gene expression, with aberrations in these processes driving tumorigenesis, immune escape, metastasis, and therapy resistance. While multi-omics technologies are generating ever more detailed maps of the histone landscape, translating these insights into clinical practice remains challenging. The ongoing convergence of high-throughput omics technologies and Artificial Intelligence (AI) is revolutionizing drug repositioning strategies, offering new precision tools to identify histone-targeted therapies for solid tumors. In this review, we explore how AI-driven multi-omics integration is currently reshaping therapeutic opportunities by uncovering novel drug-target-patient associations with unprecedented accuracy. Special focus is given to gynecologic and breast cancers, where chromatin remodeling dysregulation is particularly widespread, conventional therapeutic approaches have demonstrated substantial limitations and drug resistance represents a major clinical obstacle. These aggressive and lethal cancers exemplify areas where AI-powered repurposing of epi-drugs is making tangible clinical advances, enhancing tumor sensitivity to treatments like immunotherapy, but also offering new avenues to overcome challenging phenomena such as drug resistance and cancer relapse. We critically discuss these challenges and the effectiveness of a combination strategy approaches based on AI-driven patient stratification and biomarker-guided therapy optimization to maximize clinical benefits. In an era where precision oncology demands both specific drugs and the application of smarter strategies, the integration of AI, multi-omics, and targeting of chromatin remodelers may herald a transformative shift in the management of solid tumors, bridging the gap between biological insights and therapeutic innovation.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.